Myocarditis in Young Males After Vaccination

Another reason to stop coercing the whole population to be vaccinated

A new report was published on Christmas day looking at the risk of myocarditis following sequential COVID-19 vaccinations. It looked at over 42 million people (over 13 years of age) who were vaccinated in England between 1 December 2020 and 15 November 2021.

The authors concluded that across the entire vaccinated population, the risk of myocarditis following vaccination was small compared to the risk following a positive SARS-CoV-2 test. However, when broken down by age and sex the study revealed a disturbing pattern.

For males under the age of 40, the risk of myocarditis within 28 days after second dose vaccination was 27% higher than natural infection with AstraZeneca, 69% higher with Pfizer and a whopping 718% higher with Moderna. (The incidence rate ratios (IRR) were 2.02 with natural infection, 2.57 for AstraZeneca, 3.41 for Pfizer and 16.52 for Moderna)

There wasn’t enough data for the risks after third doses of AstraZeneca (this is no longer being used in England) and Moderna. However for Pfizer, the risk jumped from 69% (IRR = 3.41) after the second dose to 276% (IRR = 7.6) higher after the third dose - a 123% increase from dose two to three.

If we use the same percentage increases on third dose Moderna cases, the jump would be from 718% increase with a second dose to a a 1,724% increase after a third dose (IRR = 37).

Furthermore, that is the generous way of assessing the risk. If we compare the increase in risk from dose one and dose two in Pfizer and Moderna, the situation could be worse. Pfizer’s risk increased 105% and Moderna’s 606% between dose one and two - a difference of 477%.

If we use that difference between the first and second dose to look at the difference between the second and third dose we get even higher numbers for Moderna. Pfizer’s risk increased 123% between dose 2 and 3, so applying the 477% difference calculated above, equals a 709% increase for Moderna (IRR = 133.6). This would make the risk of myocarditis 6,514% higher than after natural infection!

Clearly, if this study is accurate, there should be a pause in vaccinations, especially in males under 40. Knowledge of this risk must be concerning the powers that be because only a half shot of Moderna is being administered for the booster.

I would hazard a guess that if the under 40 age groups were broken down further, we would see even higher rates, the younger the group.

Some other observations about this study include, day 0 of vaccination was not included in the data due to small numbers. I would still like to see what these numbers are.

Secondly, the baseline of which this study compared incidence rate ratios was based on individuals with a positive SARS-CoV-2 test. However, only 55% of the cases were prior to vaccination (13.5% after first dose, 30.9% after second dose and 0.9% after third). This means that almost 50% of the baseline tested positive after vaccination, meaning there is a possibility vaccinated positive cases could be skewing the figures. It would be interesting to compare only unvaccinated positive cases and use that as the baseline.

It is very clear that sequential COVID-19 vaccinations significantly increase the risk of myocarditis in males under 40. There is no reason to doubt that a fourth shot or more will further increase the risks. Even if it could be shown that the risk/benefit ratio is in favour of vaccinating certain groups, what is certain is that there should be a pause for males under 40. There should certainly not be any coercion or vaccine passports being used as a sticks and carrots to nudge young males in to being vaccinated.